 Delcath Systems, Inc. DCTH, an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced it has completed patient enrollment in its FOCUS registration trial intended to confirm the potential of its investigational combination treatment for patients with unresectable hepatic-dominant metastatic ocular melanoma mOM. Delcath expects to announce top-line results of the FOCUS trial by the middle of 2020. Because of a lack of effective treatments for patients with unresectable hepatic-dominant ocular melanoma, Delcath will continue to enroll eligible patients in the trial until Delcath determines the feasibility of an Expanded Access Program EAP and subsequent commercial availability. 